SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

March 1, 2024

https://www.globenewswire.com/news-release/2024/03/01/2838804/0/en/SELLAS-Life-Sciences-Delivers-Oral-Presentation-of-SLS009-Phase-1-Data-for-Acute-Myeloid-Leukemia-Patients-at-2024-European-School-of-Haematology-ESH-Conference.html

– All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met –

– Complete remission (CR) achieved after three months of treatment with duration of eight months and one year survival at the latest assessment –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.